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The identification of clinical predictors for the development of chronic kidney disease is a critical issue in the management of patients
with type 2 diabetes mellitus.
We evaluated 27,029 patients with type 2 diabetes mellitus and estimated glomerular filtration rate (eGFR) ≥60mL/min/1.73m2
and normoalbuminuria from the database of the Italian Association of Clinical Diabetologists network. Primary outcomes were eGFR
<60mL/min/1.73m2 and normoalbuminuria; albuminuria and eGFR ≥60mL/min/1.73m2; and eGFR <60mL/min/1.73m2 and
albuminuria. Secondary outcomes were eGFR <60mL/min/1.73m2 and albuminuria. Measurements: eGFR from serum creatinine
by chronic kidney disease epidemiology collaboration equation (CKD-EPI), urinary albumin excretion, HbA1c, triglycerides, high-
density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c), blood pressure, and body mass index.
Over a 4-year period, 33.2% of patients (n=8973) developed chronic kidney disease, 10.3% (n=2788) showed a decline in eGFR
<60mL/min/1.73m2, 18.4% (n=4978) developed albuminuria, and 4.5% (n=1207) developed both features. Relative risk ratios
(RRRs) for age (1.37, P<0.001 by 5 years), sex (0.77, P<0.001 for being male), body mass index (1.03, P<0.001 by 1kg/m2),
triglycerides (1.02, P<0.001 by 10mg/dL), and LDL-c (0.97, P=0.004 by 10mg/dL) were independently related to the onset of
eGFR reduction. Age (1.08, P<0.001 by 5 years), sex (1.36, P<0.001 for being male), body mass index (1.02, P<0.001 by 1kg/
m2), triglycerides (1.01, P=0.02 by 10mg/dL), HDL-c, and LDL-c (0.97, P=0.008 and 0.99, P=0.003 by 5 and 10mg/dL,
respectively) were related to the onset of albuminuria. HbA1c and the intensity of antihypertensive treatment showed a weaker
association with renal outcome.
Reduction in eGFR and albuminuria showed distinct sets of risk factors, suggesting that different mechanisms are involved in the
development of these 2 components of diabetic kidney disease.
Abbreviations: AMD = Associazione Medici Diabetologi, BP = blood pressure, CKD = chronic kidney disease, DKD = diabetic
kidney disease, eGFR = estimated glomerular filtration rate, HDL-c = total and high density lipoprotein cholesterol, LDL-c = low-
density lipoprotein cholesterol.
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Diabetes mellitus, mainly type 2, is a major health problem with
global estimates exceeding >380 million peoples worldwide
in the last year, thus representing 8.3% of the global adult
population.[1] This number is expected to increase to 592 million
by 2035.[2] Diabetes mellitus is currently the leading cause of
chronic kidney disease (CKD).[3] In fact, approximately 40% of
patients with diabetes develop diabetic kidney disease (DKD)
resulting in albuminuria, reduction of glomerular filtration rate
(GFR), or both.[4] DKD accounts for nearly half of all incident
cases of end-stage renal disease in the United States and 5-year
survival for patients with end-stage renal disease is <40%.[5]
The main features of DKD, that is, GFR <60mL/min/1.73m2
or albuminuria, are well-known independent predictors of
mortality, mainly from cardiovascular complications. A recent
meta-analysis has shown that the addition of GFR and urinary
albumin-to-creatinine ratio significantly improved the prediction
of cardiovascular outcomes andmortality beyond traditional risk
factors in the general population[6] as well as in patients with
diabetes mellitus,[7] and the improvement was greater with
urinary albumin-to-creatinine ratio than with GFR. Accordingly,
a new CKD classification, which includes both GFR and
albuminuria stages, has been adopted to provide more accurate
assessment of renal and cardiovascular outcomes.[8]
The typical natural history of diabetic nephropathy has been
derived mainly from studies in patients with type 1 diabetes
mellitus. In these patients, microalbuminuria is the first sign of
renal damage and may eventually progress to macroalbuminuria,
which predicts subsequent decline of GFR.[9] In contrast, the
natural history of CKD in type 2 diabetes mellitus appears to be
heterogeneous. We[10] and others[11,12] identified a subgroup of
people with type 2 diabetes mellitus who had decreased GFR
despite normoalbuminuria, whereas this particular renal feature
is associated with an increased risk of mortality,[13,14] and its
impact on the progression of kidney disease is still unclear.
Furthermore, these observations suggest that the pathophysiolo-
gy and risk factors for albuminuria and those for reduced GFR
may be different.
The present prospective study was performed on a large cohort
of patients with type 2 diabetes mellitus with preserved renal
function and normoalbuminuria at baseline with the aim of
looking for predictors of individual components of DKD and
their relationship with traditional risk factors.2. Methods
2.1. Study design, setting, patients, and data sources
In Italy, diabetes care is mainly provided by a public network of
about 700 diabetes clinics where a team of specialists provide
diagnostic confirmation, prevention, and treatment for diabetes
and its complications through close patients’ follow-up and
regular check-ups.[10,15,16]
In the present report, we analyzed a large cohort of patients
with type 2 diabetes mellitus followed-up at 207 diabetes centers
in Italy among those participating in the Italian Association of
Clinical Diabetologists (Associazione Medici Diabetologi, AMD)
initiative. The analysis was performed using the dataset of
electronic medical records collected between January 1, 2004 and
June 30, 2008. For the purpose of the analysis, we considered
only patients who were aged 18 years or older and with a follow-
up evaluation within 48±6 months complete for data about
estimated GFR (eGFR) and albuminuria. Of 68,611 patients2
identified, we excluded those with albuminuria, eGFR <60mL/
min/1.73m2 or a previous eGFR value discordant (i.e., <60mL/
min/1.73m2), or those with missing data of antidiabetic
treatment. A total of 27029 patients from 118 clinics constitute
the study population (see Fig. 1, Supplemental Content, http://
links.lww.com/MD/B102). The centers involved in the study
include about one-third of all the Italian Centers for Diabetes,
homogeneously distributed throughout the country.2.2. Methods and data collection
As already reported,[10,15,16] the analysis of the database is an
attempt by the Italian Association of AMD initiative to identify a
set of indicators that can be used in the context of continuous
quality improvement. Participating centers adopted the same
software systems for everyday management of outpatients,
whereas a specially developed software package allowed us to
extract the information we intended to analyze from all the
clinical databases (AMD Data File). Moreover, data from all
participating centers were collected and centrally analyzed
anonymously.[10,15,16] In the AMD database, data can be linked
together by a unique anonymous identifier that is encrypted to
protect patients’ privacy. Because this automated system
precludes identification of individual patients, according to the
Italian law, ethical committee approval and informed consent
were not required. The results were internally approved by the
AMD Annals Scientific Committee.
This initiative includes measuring and monitoring HbA1c,
blood pressure (BP), low-density lipoprotein cholesterol (LDL-c),
total and high-density lipoprotein cholesterol (HDL-c), and
triglycerides. The use of specific classes of drugs (insulin, statins,
and≥2 antihypertensive agents) was also evaluated. Since normal
ranges for HbA1c varied among centers, the percentage change
with respect to the upper normal value (measured value/upper
normal limit) was estimated and multiplied by 6.0 to allow
comparisons among the centers. Kidney function was assessed by
serum creatinine and urinary albumin excretion measurements.
GFR was estimated for each patient using a standardized serum
creatinine assay and the Chronic Kidney Disease Epidemiology
Collaboration formula.[17] Increased urinary albumin excretion
was diagnosed and defined as albuminuria if urinary albumin
concentration was >30mg/L or urinary albumin excretion
rate was >20mg/min or urinary albumin-to-creatinine ratio
was >2.5mg/mmol in men and >3.5mg/mmol in women. At
each participating center, all patients underwent physical
examination and BP measurements according to a standardized
protocol. BP was measured with the patient in the sitting position
after a 5-minute rest, with a mercury sphygmomanometer.
Systolic BP and diastolic BP were read to the nearest 2mmHg.
Disappearance of Korotkoff sounds (phase V) was the criterion
for diastolic BP. Three measurements were taken at 2-minute
intervals and the average value was used to define clinical systolic
BP and diastolic BP. CKD was defined as diabetes with
albuminuria or low eGFR (i.e., <60mL/min/1.73m2) or both.2.3. Outcomes
The primary outcomes were eGFR <60mL/min/1.73m2 and
normoalbuminuria; albuminuria and eGFR ≥60mL/min/
1.73m2; and eGFR <60mL/min/1.73m2 and albuminuria.
Secondary outcomes were eGFR <60mL/min/1.73m2 and
albuminuria. Occurrence of prespecified endpoints was evaluated
on a yearly basis over the 4-year study period. Patients were
De Cosmo et al. Medicine (2016) 95:27 www.md-journal.comconsidered to have reached the study endpoints if, at any time
during the study period, they met the above indicated criteria.
We have also evaluated the occurrence of a GFR decline>30%
from baseline value.[18]2.4. Statistical analysis
The data are given as mean value± standard deviation; categorical
variables are described as frequencies and percentages.
Statistical analysis was aimed to investigate factors associated to
individual components of DKD. Themain analysis was performed
using a multinomial logistic regression model considering 4
outcome categories: eGFR ≥60mL/min/1.73m2 and normoalbu-
minuria; eGFR <60mL/min/1.73m2 and normoalbuminuria;
GFR ≥60mL/min/1.73m2 and albuminuria; and eGFR <60mL/
min/1.73m2 and albuminuria. In comparison to classic logistic
regression analysis that evaluates a dependent variable with 2
alternative categories, themultinomial logistic regression estimates
in a unique model the RRRs for observing a dependent variable
with more categories (4 distinct DKD outcomes) as a function of
independent covariates (baseline data).
The relative risk ratios (RRRs) were used to estimate the degree
of association between baseline patients’ data and each single
outcome considering those without DKD development as the
reference category.Table 1
Baseline clinical characteristics by renal outcome.
Overall Alb
n=27,029 n=
Male sex, n (%) 15,249 (56.4%) 10,14
Age, y 64±10 6
Known duration of diabetes, y 10±8 1
BMI, kg/m2 29.2±5 28
Serum creatinine, mg/dL 0.85±0.17 0.8
eGFR, mL/min/1.73m2 85±13 8
eGFR >90mL/min/1.73m2, n (%) 10,341 (38.3%) 7908
HbA1c (%) 7.2±1.3 7.
HbA1c ≥7% (53 mmol/mol), n (%) 14,194 (52.9%) 9156
Total cholesterol, mg/dL 188±36 18
Triglycerides, mg/dL 133±88 12
Triglycerides ≥150mg/dL, n (%) 7484 (29.2%) 4727
HDL-c, mg/dL 52±15 5
HDL-c <40mg/dL if male, <50mg/dL if female, n (%) 7183 (28.3%) 4539
LDL-c, mg/dL 111±32 11
LDL-c ≥100mg/dL, n (%) 15,523 (61.9%) 10,58
Systolic BP, mmHg 139±18 13
Diastolic BP, mmHg 80±9 8
Systolic/diastolic BP ≥140/85mmHg, n (%) 13,702 (59.1%) 8828
Retinopathy, n (%) 2510 (9.3%) 1,49
Lipid-lowering treatment, n (%) 11,664 (43.2%) 7520
Treatment with statins, n (%) 10,682 (39.5%) 6912
Treatment with fibrates, n (%) 579 (2.1%) 36
Antihypertensive treatment, n (%) 15,995 (59.2%) 9871
Treatment with ACE-Is/ARBs, n (%) 13,284 (49.1%) 8104
Aspirin, n (%) 5373 (19.9%) 3305
Antidiabetic therapy
Diet, n (%) 2843 (10.5%) 2179
Oral antidiabetic drugs, n (%) 18,035 (66.7%) 12,14
Oral antidiabetic drugs and insulin, n (%) 3294 (12.2%) 1906
Insulin, n (%) 2857 (10.6%) 1830
Mean±SD or absolute frequency (percentage). ACE-Is= angiotensin converting enzyme-inhibitors, Alb=no
BP=blood pressure, eGFR= estimated glomerular filtration rate, BMI=body mass index, eGFR= eGFR ≥6
density lipoprotein cholesterol, LDL-c= low-density lipoprotein cholesterol. The P value refers to model significan
in 811 (3.0%), BMI in 3447 (12.8%), HbA1c in 210 (0.8%), total cholesterol in 1201 (4.4%), triglycerides
3
A multi-level mixed-effects logistic regression model was used
to evaluate single outcome (i.e., eGFR <60mL/min/1.73m2 and
albuminuria). Data were analyzed considering diabetes clinics as
clusters of observations, so that possible differences in data across
centers could be considered. RRRs were reported with their 95%
confidence interval. The multivariate model was fitted including a
missing indicator variable for patients with missing data. A
complete-case analysis was performed including patients for
which all data were observed. Multivariate analyses were
performed adjusting for all baseline clinical characteristics. To
derive a hierarchical tree of event risk, a logistic model for renal
outcome (separately for eGFR <60mL/min/1.73m2 and albu-
minuria) was used to split the data recursively into subgroups
selecting the variable with the minimum P value. Continuous
variables were analyzed for all values from the 5th to 95th
percentile selecting the best cut-point with the lowest P value. The
tree-building process was stopped after 3 iterations to obtain 8
groups. The analyses were made using STATA software, Version
12 (StataCorp, College Station, TX). P values of <0.05 were
considered statistically significant.3. Results
The main clinical features of the study population (n=27,029) at
baseline, as a whole, and grouped by renal outcomes at 4-year/eGFR Alb/eGFR+ Alb+/eGFR Alb+/eGFR+
18,056 n=2788 n=4978 n=1207 P
6 (56.2%) 1296 (46.5%) 3156 (63.4%) 651 (53.9%) <0.001
3±10 69±8 64±10 69±8 <0.001
0±8 12±9 10±8 12±9 <0.001
.9±4.9 29.6±4.8 29.5±5.1 29.9±5 <0.001
3±0.16 0.92±0.16 0.84±0.16 0.94±0.16 <0.001
7±13 74±10 87±13 74±10 <0.001
(43.8%) 226 (8.1%) 2103 (42.2%) 104 (8.6%) <0.001
2±1.2 7.3±1.3 7.3±1.3 7.6±1.4 <0.001
(51.1%) 1559 (56.4%) 2751 (55.7%) 728 (61%) <0.001
9±36 188±37 186±37 185±37 <0.001
9±84 139±94 140±96 148±91 <0.001
(27.7%) 821 (31.2%) 1510 (31.8%) 426 (37.1%) <0.001
3±15 52±15 51±15 50±15 <0.001
(26.8%) 774 (29.6%) 1486 (31.5%) 384 (33.9%) <0.001
2±32 110±33 109±33 107±34 <0.001
5 (63.3%) 1547 (60.2%) 2759 (59.3%) 632 (56.8%) <0.001
8±18 142±18 139±18 143±18 <0.001
0±9 80±9 80±9 80±9 0.91
(57.4%) 1489 (64.4%) 2670 (60.2%) 715 (69.2%) <0.001
9 (8.3%) 318 (11.4%) 541 (10.9%) 152 (12.6%) <0.001
(41.6%) 1293 (46.4%) 2272 (45.6%) 579 (48%) <0.001
(38.3%) 1166 (41.8%) 2078 (41.7%) 526 (43.6%) 0.001
3 (2%) 83 (3%) 105 (2.1%) 28 (2.3%) 0.009
(54.7%) 1986 (71.2%) 3232 (64.9%) 906 (75.1%) <0.001
(44.9%) 1658 (59.5%) 2732 (54.9%) 790 (65.5%) <0.001
(18.3%) 717 (25.7%) 1038 (20.9%) 313 (25.9%) <0.001
(12.1%) 249 (8.9%) 379 (7.6%) 36 (3%) <0.001
1 (67.2%) 1783 (64%) 3359 (67.5%) 752 (62.3%) 0.001
(10.6%) 423 (15.2%) 721 (14.5%) 244 (20.2%) <0.001
(10.1%) 333 (11.9%) 519 (10.4%) 175 (14.5%) <0.001
rmoalbuminuria, Alb+= albuminuria, ARBs= angiotensin II receptor antagonists, BMI=body mass index,
0mL/min/1.73m2, eGFR+= eGFR<60mL/min/1.73m2, HbA1c=glycated hemoglobin, HDL-c=high-
ce of univariate multinomial logistic regression. Patients’ baseline missing data: known duration of diabetes
in 1435 (5.3%), HDL-c in 1638 (6.1%), LDL-c in 1970 (7.3%), and blood pressure in 3862 (14.3%).
De Cosmo et al. Medicine (2016) 95:27 Medicinefollow-up are summarized in Table 1. Overall, the mean age was
64±10 years, 56.4% of patients were males, and the mean
duration of diabetes was 10±8 years. Thirty-eight percent of
patientswereobese (i.e., theyhadaBMI≥30kg/m2).The glycemic,
lipid, and BP control of participants was fairly good, being the
mean values of HbA1c, LDL-c, and BP of 7.2% (55mmol/mol),
111mg/dL, and 139/80mmHg, respectively. EGFR was 85±13
mL/min/1.73m2 (Table 1). By studydesign, all patients hadnormal
urine albumin excretion and eGFR ≥60mL/min/1.73m2.
Over a 4-year follow-up period, a total of 33.2% of patients
(n=8973) developed CKD (i.e., eGFR <60mL/min or albumin-
uria). According to the main aim of this work, we separately
report the clinical features of patients in whom kidney function
remained stable (n=18,056, 66.8%) and of those who developed
reduced eGFR alone (i.e., eGFR<60mL/min/1.73m2) (n=2788,
10.3%), albuminuria alone (n=4978, 18.4%) or both, reduced
eGFR, and albuminuria (n=1207, 4.5%) over a 4-year follow-
up. Patients who developed reduced eGFR in the presence of
normoalbuminuria represent 70% of the whole population who
developed low eGFR (n=3995) and 13% of those who remained
normoalbuminuric at follow-up (n=20,844). As compared to
those whose kidney function remained stable at follow-up, they
were more likely to be women and, on the average, older, with a
longer duration of disease and a poor glycemic control. As
expected, they had also a lower eGFR at baseline (74 vs. 87mL/
min/1.73m2, patients who developed low eGFR and patients
who remained with stable eGFR, respectively). Reduced eGFR at
follow-up was associated also with a more atherogenic lipid
profile (i.e., higher triglycerides and lower HDL-c) and higher
systolic BP, the latter despite a parallel trend toward greater
prevalence and intensity (i.e., number of drugs, data not shown)
of antihypertensive treatment (Table 1).
Patients who developed albuminuria in presence of eGFR ≥60
mL/min/1.73m2 (n=4978) are 80% of the whole populationTable 2
Multivariate relative-risk ratios for renal outcomes.
RRR for Alb/eGFR+ P
Male sex 0.767 (0.681–0.864) <0.001
Age (by 5 years) 1.373 (1.326–1.422) <0.001
Known duration of diabetes (by 5 years) 1.020 (0.982–1.059) 0.3
BMI (by 1kg/m2) 1.033 (1.020–1.046) <0.001
Baseline eGFR (by 10) <90 mL/min/1.73m2 2.614 (2.434–2.807) <0.001
HbA1c (%) 1.049 (0.989–1.112) 0.1
Triglycerides (by 10 mg/dL) 1.018 (1.009–1.026) <0.001
HDL-c (by 5mg/dL) 0.981 (0.958–1.004) 0.1
LDL-c (by 10mg/dL) 0.974 (0.957–0.992) 0.004
Systolic BP (by 5mmHg) 1.013 (0.996–1.030) 0.1
Retinopathy 1.181 (0.991–1.409) 0.06
Treatment with statins 0.984 (0.880–1.099) 0.8
Treatment with fibrates 1.197 (0.884–1.621) 0.2
Antihypertensive treatment 1.327 (1.085–1.623) 0.006
Treatment with ACE-Is/ARBs 1.075 (0.922–1.255) 0.4
Aspirin 1.079 (0.909–1.280) 0.4
Antidiabetic therapy
Diet 0.852 (0.67–1.084) 0.2
Oral antidiabetic drugs 1.00 —
Oral antidiabetic drugs and insulin 1.315 (1.065–1.624) 0.01
Insulin 1.238 (1.022–1.501) 0.03
Complete case analysis performed by using a multinomial logistic regression model including 19,482 p
angiotensin converting enzyme-inhibitors, ARBs=angiotensin II receptor antagonists, Alb=normoalbumi
filtration rate, eGFR= eGFR ≥60mL/min/1.73m2, eGFR+= eGFR <60mL/min/1.73m2, HbA1c=g
cholesterol.
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who developed albuminuria (n=6185) and 21.6% of those
who remained with eGFR ≥60mL/min/1.73m2 at follow-up
(n=23,034). As compared to patients whose kidney function
remained stable at follow-up, those who developed albuminuria
were prevalently males and show a worse glycemic control. They
clearly have a more atherogenic lipid profile. Systolic BP is only
slightly increased in patients developing albuminuria, despite a
parallel trend toward greater prevalence and intensity (i.e.,
number of drugs, data not shown) of antihypertensive treatment
(Table 1).
Patients who developed both low eGFR and albuminuria (n=
1207) showed a worse cardiovascular risk factors profile when
compared to patients who did not develop renal abnormalities.
They were prevalently males and older, had a longer duration of
disease, poor glycemic control, lower eGFR, more atherogenic
lipid profile, and higher systolic BP values. Furthermore, a greater
number of patients taking antihypertensive, lipid-lowering, and
hypoglycemic drugs was also evident among these patients.
In the Table 4, Supplemental Content, http://links.lww.com/
MD/B102, we have reported the baseline clinical features of 2175
(8.1%) patients who develop a reduction of eGFR >30% from
baseline value.
The relationship between the onset of DKD traits and
traditional cardiovascular risk factors was further investigated
by multivariate logistic analysis (Table 2, Fig. 1). Age, but not
duration of disease, independently affects both features of CKD,
with a 5-year increase in risk of 37% for the development of low
eGFR and of 7.5% for albuminuria, respectively. Being female
clearly represents an independent risk factor for developing
normoalbuminuric renal impairment (i.e., isolated reduced
eGFR), whereas males are at increased risk for developing
albuminuria.
Worse glycemic control also affected the onset of albuminuria
with an increased risk of 7% for every 1% increase in HbA1c,RRR for Alb+/eGFR P RRR for Alb+/eGFR+ P
1.355 (1.220–1.504) <0.001 1.090 (0.926–1.283) 0.30
1.075 (1.033–1.118) <0.001 1.381 (1.306–1.460) <0.001
0.981 (0.947–1.017) 0.3 1.001 (0.950–1.056) 0.96
1.019 (1.012–1.026) <0.001 1.036 (1.022–1.050) <0.001
1.000 (0.935–1.069) 0.9 2.837 (2.592–3.105) <0.001
1.069 (1.001–1.141) 0.04 1.100 (1.019–1.188) 0.01
1.008 (1.001–1.015) 0.02 1.031 (1.022–1.041) <0.001
0.973 (0.954–0.993) 0.008 0.936 (0.905–0.969) <0.001
0.980 (0.967–0.993) 0.003 0.957 (0.933–0.981) <0.001
1.000 (0.985–1.016) 0.9 1.022 (0.998–1.047) 0.07
1.112 (0.931–1.329) 0.2 1.135 (0.874–1.473) 0.34
1.034 (0.901–1.187) 0.6 1.041 (0.894–1.212) 0.60
0.887 (0.670–1.174) 0.4 0.665 (0.400–1.104) 0.11
1.150 (1.008–1.313) 0.04 1.228 (0.968–1.558) 0.09
1.185 (1.039–1.353) 0.01 1.441 (1.165–1.783) 0.001
0.938 (0.786–1.120) 0.5 0.994 (0.821–1.204) 0.95
0.675 (0.488–0.935) 0.02 0.318 (0.210–0.481) <0.001
1.00 — 1.00 —
1.287 (1.021–1.623) 0.03 1.879 (1.423–2.481) <0.001
1.087 (0.877–1.348) 0.4 1.639 (1.274–2.110) <0.001
atients for which all data were observed. Mean±SD or absolute frequency (percentage). ACE-Is=
nuria, Alb+= albuminuria, BMI=body mass index, BP=blood pressure, eGFR= estimated glomerular
lycated haemoglobin, HDL-c=high-density lipoprotein cholesterol, LDL-c= low-density lipoprotein
Figure 1. Multivariate relative risk ratios (RRRs) with their 95% confidence intervals (95% CIs) to develop estimated glomerular filtration rate <60mL/min/1.73m2
(Alb/eGFR+)=albuminuria (Alb+/eGFR)=or both (Alb+/eGFR+). Antidiabetic therapy was analyzed by using oral antidiabetic drugs as reference category.
Analysis performed by using a multinomial logistic regression model with the missing indicator method for each incomplete variable.
De Cosmo et al. Medicine (2016) 95:27 www.md-journal.comwhile it would appear not to have any clinical relevance with
regard to the risk of low eGFR. Higher BP levels predict the onset
of albuminuria and low eGFR with albuminuria; in fact patients
with uncontrolled BP (i.e., systolic/diastolic BP ≥140/85mmHg)
have a 33% increased risk of simultaneously developing both
kidney dysfunctions traits (i.e., low eGFR and albuminuria)
(Table 2).
DKD onset was also predicted by the typical atherogenic lipid
profile. In fact, high levels of triglycerides were directly associated
with an increased probability to develop reduced eGFR and/or
albuminuria, whereas HDL-c levels inversely affected the risk of
developing albuminuria (Table 2, Fig. 2).
We also looked at patients who developed low eGFR or
albuminuria, independently of each other. The cumulative
incidence of low eGFR (i.e., eGFR <60mL/min/1.73m2) in the
whole population or divided according to eGFR values >90 or
<90 and >60mL/min/1.73m2 is reported in Fig. 2, panel A. As
expected, the incidence of low eGFR increased progressively over
the 4-year follow-up period and was higher among patients with
a lower eGFR at baseline (i.e., 60–90mL/min/1.73m2). The
cumulative incidence of albuminuria also showed a progressive
increase during follow-up (Fig. 2, panel B).Figure 2. Proportion by year of patients with estimated glomerular filtration rate (
baseline assessments. Number of evaluations were 27,029, 16,235, 17,591, 80
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Finally, by applying a tree analysis model, we identified 8
patient subgroups at different risk for developing eGFR <60mL/
min/1.73m2 with the strongest variable in differentiating the risk
being baseline eGFR value. In fact, patients with baseline eGFR
≥75mL/min/1.73m2, associated with age <65 years and male
sex, showed the lowest incidence of eGFR <60mL/min/1.73m2.
If this is considered as the reference class (class 8), the incidence of
low eGFR progressively increases from class 8 to class 1, whose
patients are more often females, have a lower eGFR and higher
HbA1c values at baseline, and are prescribed more antihyper-
tensive therapy (see Fig. 2 and Table 5, Supplemental Content,
http://links.lww.com/MD/B102).
As for albuminuria, 8 different subgroups were identified by
tree analysis model. The strongest variable in differentiating
the risk of developing albuminuria was HDL-c values. In detail,
patients with HDL-c ≥50mg/dL, age <69 years, and HbA1c
<7.5% (58mmol/mol) had the lowest incident rate of albumin-
uria (17.3%). If this is considered the reference class, the
incidence of albuminuria progressively increases from class 8 to
class 1 (44.1%), whose patients have lower HDL-c and eGFR
values at baseline and are more often taking insulin therapy. In
addition, a greater number of these latter patients are males, haveeGFR) <60mL/min/1.73m2 (panel A) and albuminuria (panel B) at the 4 post-
19, and 27,029 at baseline, 1, 1, 3, and 4 year, respectively.
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therapy (see Fig. 3 and Table 6, Supplemental Content, http://
links.lww.com/MD/B102).4. Discussion
Our study shows that in a real-life clinical setting, up to 33.2% of
patients with type 2 diabetes mellitus develop CKD over a 4-year
follow-up period. Overall, the incidence of renal outcome
reported here is in line with what has been previously
described[5,19–22] in patients with similar disease duration. The
incidence of DKD we report here is similar to what has been
previously described[23] and significantly higher than the figure
recently reported in the general population,[18,24] making
diabetes mellitus in its own right a tremendous risk factor for
CKD.
We found a relatively greater incidence of renal events during
the first study year, owing to disease progression in the subset of
patients with GFR values only slightly above 60mL/min/1.73m2
at baseline. Subsequently, the average yearly rate of progression
was 0.5% to 1.0% for GFR reduction and 1% to 2% for
albuminuria onset, independently of baseline GFR. The study
cohort, which had a mean GFR value at baseline of 85mL/min/
1.73m2, showed a yearly decrement of 1mL/min/1.73m2 (P<
0.001). More patients developed albuminuria (18%) rather than
renal impairment (10% eGFR <60mL/min/1.73m2), whereas a
minority (i.e., 5%) developed both features of CKD. A total of
8.1% of study patients reached the secondary endpoint of a GFR
reduction >30% compared to baseline. However, the vast
majority of these patients (i.e., 81%) also reached the primary
endpoint of an eGFR<60mL/min/1.73m2. Determinants of GFR
reduction in this subgroup were similar to those identified for the
primary endpoints. The considerable discordance we found in the
incidence of these 2 renal outcomes is in line with previously
published longitudinal[19–22,25] and cross-sectional studies[26,27]
and adds to the concept that renal involvement is a rather
heterogeneous condition in type 2 diabetes mellitus, and therefore
differs significantly from the traditional clinical paradigm
observed in type 1 diabetes mellitus. Whereas albuminuria and
renal impairment shared a number of risk factors, such as age,
BMI, lipid profile, and the amount of antihypertensive and
glucose-lowering treatment, there also was a distinct set of
variables, which predicted one but not the other. In fact,
reduction of GFR below 60mL/min/1.73m2 was more likely to
be associated with female sex and triglycerides levels, while
albuminuria wasmore frequently observed in men and in patients
with higher HbA1c levels (and lowHDL-c). These results support
the concept that albuminuria and renal impairment may not
necessarily reflect the same underlying pathophysiological
mechanism in type 2 diabetes mellitus.
Owing to the stringent selection criteria of the study, our
results cannot provide information on the potential role of
baseline albuminuria on the loss of GFR overtime. However, by
looking at a rather homogenous cohort of patients who, after a
mean 10-year disease duration, presented no sign of renal
involvement at baseline, we could better investigate the role of
hypertension, lipid profile, and hyperglycemia as renal disease
promoters. In fact, the majority of patients with diabetes-
unrelated causes of renal damage were likely excluded from our
study cohort on the basis of selection criteria.
As most of our study patients were already under hypertensive
treatment at baseline, the lack of a relationship between BP and
renal outcomes is not surprising. We found, however, a strong6
relationship between antihypertensive treatment, especially the
use of renin-angiotensin system inhibiting drugs, and renal
outcome (Table 2 and Fig. 1), probably because of indication
bias. Indirectly, we take this as a sign of the unfavorable influence
of the severity of hypertension on renal outcome.
As for the role of glycometabolic control, we found thatHbA1c
was related to albuminuria but not to the development of low
GFR. This is partly at variance with what has been previously
reported[22,25] but in line with data from UKPDS[20] and other
more recent studies.[28,29] Such discrepancies may be attributable
to differences in the inclusion criteria or ethnicity, as well as
possible differences in definitions used for outcomes. In addition,
one should bear in mind that our cohort had, on average, a
relatively good glycometabolic control, with HbA1c values well
below 7% (53mmol/mol) in >50% of cases.
A greater incidence of renal endpoints was positively
associated with triglycerides levels and negatively with HDL-c.
The predictive power of these lipid abnormalities, traditionally
considered a surrogate for the insulin resistance state, together
with the observed relationship between BMI and subsequent
development of albuminuria, renal impairment or both, supports
a role for the metabolic syndrome and insulin resistance in the
progression of renal damage.[30,31] Accordingly, Penno et al have,
very recently, confirmed in a cross-sectional study the indepen-
dent association between hypertriglyceridemia and CKD among
patients with type 2 diabetes mellitus.[32]
The tree analysis allowed us to investigate also the interaction
between several clinical variables and their hierarchical impact on
the incidence of reduced eGFR or albuminuria. The results of this
analysis show that patients with lower GFR values, older age, and
longer duration of diabetes have a 49% risk of developing eGFR
<60mL/min/1.73m2. Moreover, features of the metabolic
syndrome, mainly low HDL-c levels, and high triglycerides
entail a 4-fold greater risk of developing albuminuria.
Our study has some limitations as well as several strengths that
should be mentioned. Among the first, wemust acknowledge that
laboratory parameters, including serum creatinine, were not
measured in a single centralized laboratory and this may have led
to some variability, especially in GFR estimation. In addition, we
have information on albuminuria only as a categorical trait and
this, together with some heterogeneity in the techniques used to
measure urinary albumin concentration in different laboratories,
may have contributed to variability in the outcome measure.
Moreover, data regarding the entire 4-year follow-up periodwere
available for most but not all patients and therefore caution
should be taken not to generalize our findings, as mortality from
competitive risk was not positively collected in the missing
subgroup. Baseline clinical features of the subgroup with missing
values, however, were similar to that of the entire cohort.
Furthermore, even when less stringent selection criteria were
applied to our study cohort, our main results remained
unchanged. Finally, our data may not be applicable to the
population of patients with type 2 diabetes mellitus at large, as
the vast majority of participants were of white origin and
ethnicity has previously been shown to bear some impact on the
risk of developing renal complications.[33] However, we should
mention the large size of the study cohort and the homogeneous
geographical distribution of the recruiting centers as well as the
relatively long follow-up period, which certainly contribute in
making the study cohort a good representation of real-life clinical
practice.
In conclusion, our 4-year prospective study of a large, real-life
cohort of patients with type 2 diabetes mellitus with normal renal
[16] De Cosmo S, Viazzi F, Pacilli A, et al. Serum uric acid and risk of chronic
De Cosmo et al. Medicine (2016) 95:27 www.md-journal.comfunction at baseline showed a 33.2% cumulative incidence of
CKD, with nearly 23% of patients developing albuminuria and
about 15% renal impairment. Albuminuria and reduction in
GFR show, at least in part, distinct sets of risk factors suggesting
that different pathophysiological mechanisms are involved in the
development of these renal outcomes.References
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